This invention provides formulations for use in distributing RNAi molecules targeted to a human GST-π for treating a malignant tumor in a subject. The formulation can include nanoparticles composed of an ionizable lipid, a DSPE lipid, and additional lipids. A drug product can be made by lyophilization of the formulation. This invention further provides methods for ameliorating or treating a malignant tumor by administering a therapeutically effective amount of a formulation containing the RNAi agents.

Polypeptides that are glutathione-S-transferases originating from different schistosome parasites, as well as nucleic acids, vectors, compositions or kits, for use in the preventive or therapeutic treatment of vasculitis or of a disease characterized by a M1/M2 macrophage ratio dysregulation, such as e.g. a decrease of the M1-type immune response and/or an increase of the M2-type immune response.

The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.

Described are engineered cells that include genetic alterations leading to up- or down-regulation of certain genes in the cells for improved production of a recombinant protein, especially one that is not easily expressed at high levels in unaltered cell lines. Also provided are methods of preparing and using such cells.

The present invention relates to a method for screening protein-protein interaction inhibitors using a nanopore, a method for analyzing protein structures, a method for analyzing protein-protein interactions, and a kit therefor.

Provided is a method for degrading epoxy resins by enzymatic route, in particular by adding an epoxy resin in a solvent followed by treatment with a glutathione S-transferase. A method for recycling a composite material comprising epoxy resin as well as the use of glutathione 5-transferase and eventually para-hydroxybenzoate hydroxylase for degrading epoxy resins are also provided.

The present invention relates to a new zinc binding fusion protein that is a fusion protein of glutathione S-transferase (GST) and metallothionein (MT), to which zinc bind, providing an efficacy in preventing or treating a ROS-related disease and heavy metal poisoning.

Compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

Mice comprising a transgene encoding a peptide (iBox) inhibitor of Group B p21-activated kinase are provided. Also provided are cells, tissue, and organs obtained from such transgenic mice. Also provided are methods for producing mice comprising an iBox-encoding transgene.

The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.